The economic cost of brain disorders in Europe
- PMID: 22175760
- DOI: 10.1111/j.1468-1331.2011.03590.x
The economic cost of brain disorders in Europe
Abstract
Background and purpose: In 2005, we presented for the first time overall estimates of annual costs for brain disorders (mental and neurologic disorders) in Europe. This new report presents updated, more accurate, and comprehensive 2010 estimates for 30 European countries.
Methods: One-year prevalence and annual cost per person of 19 major groups of disorders are based on 'best estimates' derived from systematic literature reviews by panels of experts in epidemiology and health economics. Our cost estimation model was populated with national statistics from Eurostat to adjust to 2010 values, converting all local currencies to Euros (€), imputing cost for countries where no data were available, and aggregating country estimates to purchasing power parity-adjusted estimates of the total cost of brain disorders in Europe in 2010.
Results: Total European 2010 cost of brain disorders was €798 billion, of which direct health care cost 37%, direct non-medical cost 23%, and indirect cost 40%. Average cost per inhabitant was €5.550. The European average cost per person with a disorder of the brain ranged between €285 for headache and €30 000 for neuromuscular disorders. Total annual cost per disorder (in billion € 2010) was as follows: addiction 65.7; anxiety disorders 74.4; brain tumor 5.2; child/adolescent disorders 21.3; dementia 105.2; eating disorders 0.8; epilepsy 13.8; headache 43.5; mental retardation 43.3; mood disorders 113.4; multiple sclerosis 14.6; neuromuscular disorders 7.7; Parkinson's disease 13.9; personality disorders 27.3; psychotic disorders 93.9; sleep disorders 35.4; somatoform disorder 21.2; stroke 64.1; and traumatic brain injury 33.0.
Conclusion: Our cost model revealed that brain disorders overall are much more costly than previously estimated constituting a major health economic challenge for Europe. Our estimate should be regarded as conservative because many disorders or cost items could not be included because of lack of data.
© 2011 The Author(s). European Journal of Neurology © 2011 EFNS.
Comment in
-
Is there underfunding in brain research? The UK research expenditure.Eur J Neurol. 2012 Jan;19(1):4-5. doi: 10.1111/j.1468-1331.2011.03499.x. Epub 2011 Sep 14. Eur J Neurol. 2012. PMID: 21914051 No abstract available.
Similar articles
-
Cost of disorders of the brain in Europe 2010.Eur Neuropsychopharmacol. 2011 Oct;21(10):718-79. doi: 10.1016/j.euroneuro.2011.08.008. Epub 2011 Sep 15. Eur Neuropsychopharmacol. 2011. PMID: 21924589
-
Cost estimates of brain disorders in Belgium.Acta Neurol Belg. 2006 Dec;106(4):208-14. Acta Neurol Belg. 2006. PMID: 17323838
-
Cost of depression in Europe.J Ment Health Policy Econ. 2006 Jun;9(2):87-98. J Ment Health Policy Econ. 2006. PMID: 17007486
-
Estimating the cost of epilepsy in Europe: a review with economic modeling.Epilepsia. 2007 Dec;48(12):2224-33. doi: 10.1111/j.1528-1167.2007.01251.x. Epilepsia. 2007. PMID: 18088267 Review.
-
Cost of disorders of the brain in Spain.PLoS One. 2014 Aug 18;9(8):e105471. doi: 10.1371/journal.pone.0105471. eCollection 2014. PLoS One. 2014. PMID: 25133395 Free PMC article. Review.
Cited by
-
Temporal trends in inpatient care use for adult mental disorders in Czechia: a nationwide register-based study from 1994 to 2015.Soc Psychiatry Psychiatr Epidemiol. 2024 May 31. doi: 10.1007/s00127-024-02691-5. Online ahead of print. Soc Psychiatry Psychiatr Epidemiol. 2024. PMID: 38819518
-
Migraine or any headaches and white matter hyperintensities and their progression in women and men.J Headache Pain. 2024 May 15;25(1):78. doi: 10.1186/s10194-024-01782-7. J Headache Pain. 2024. PMID: 38745272 Free PMC article.
-
Structural Neuroplasticity Effects of Singing in Chronic Aphasia.eNeuro. 2024 May 13;11(5):ENEURO.0408-23.2024. doi: 10.1523/ENEURO.0408-23.2024. Print 2024 May. eNeuro. 2024. PMID: 38688718 Free PMC article. Clinical Trial.
-
Genomics of Brain Disorders 4.0.Int J Mol Sci. 2024 Mar 25;25(7):3667. doi: 10.3390/ijms25073667. Int J Mol Sci. 2024. PMID: 38612479 Free PMC article.
-
Placebo Effects Are Small on Average in the 7.5% CO2 Inhalational Model of Generalized Anxiety.Int J Neuropsychopharmacol. 2024 Apr 1;27(4):pyae019. doi: 10.1093/ijnp/pyae019. Int J Neuropsychopharmacol. 2024. PMID: 38577951 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical